Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses · 2023
DOI: 10.3390/v15102066 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2023. Verfasst von José Luis Piñana und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Clínico Universitario, 46017 Valencia, Spain. Hauptthemen laut MEDLINE: Coinfection, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Scarce data exist that analyze the outcomes of hematological patients with SARS-CoV-2 infection during the Omicron variant period who received treatment with remdesivir or nirmatrelvir/ritonavir.
Methods
This study aims to address this issue by using a retrospective observational registry, created by the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group, spanning from 27 December 2021 to 30 April 2023.
Results
This study included 466 patients, 243 (52%) who were treated with remdesivir and 223 (48%) with nirmatrelvir/ritonavir. Nirmatrelvir/ritonavir was primarily used for mild cases, resulting in a lower COVID-19-related mortality rate (1.3%), while remdesivir was preferred for moderate to severe cases (40%), exhibiting a higher mortality rate (9%). A multivariate analysis in the remdesivir cohort showed that male gender (odds ratio (OR) 0.35, p = 0.042) correlated with a lower mortality risk, while corticosteroid use (OR 9.4, p < 0.001) and co-infection (OR 2.8, p = 0.047) were linked to a higher mortality risk. Prolonged virus shedding was common, with 52% of patients shedding the virus for more than 25 days. In patients treated with remdesivir, factors associated with prolonged shedding included B-cell malignancy as well as underlying disease, severe disease, a later onset of and shorter duration of remdesivir treatment and a higher baseline viral load. Nirmatrelvir/ritonavir demonstrated a comparable safety profile to remdesivir, despite a higher risk of drug interactions.
Conclusions
Nirmatrelvir/ritonavir proved to be a safe and effective option for treating mild cases in the outpatient setting, while remdesivir was preferred for severe cases, where corticosteroids and co-infection significantly predicted worse outcomes. Despite antiviral therapy, prolonged shedding remains a matter of concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital Clínico Universitario, 46017 Valencia, Spain.
- INCLIVA, Biomedical Research Institute, 46017 Valencia, Spain.
- Hematology Division, Hospital Morales Meseguer, 30100 Murcia, Spain.
- Infectious Disease Division, Hospital Clinic, 08193 Barcelona, Spain.
- Hematology Division, Hospital de la Santa Creu i Sant Pau, 08193 Barcelona, Spain.
- Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain.
ORCID-Profile: Tommaso Francesco Aiello, Pedro Chorão, Carolina García-Vidal, Lucia López-Corral, Valentín Garcia-Gutierrez, José Ángel Hernández-Rivas, Manuel Guerreiro, Rodrigo Martino, Carlos Solano
Zitieren
APA
Piñana, J. L., Heras, I., Aiello, T. F., García-Cadenas, I., Vazquez, L., Lopez-Jimenez, J., Chorão, P., Aroca, C., García-Vidal, C., Arroyo, I., Soler-Espejo, E., López-Corral, L., Avendaño-Pita, A., Arrufat, A., Garcia-Gutierrez, V., Arellano, E., Hernández-Medina, L., González-Santillana, C., Morell, J., …, & Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC) (2023). Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. https://doi.org/10.3390/v15102066
Vancouver
Piñana JL, Heras I, Aiello TF, García-Cadenas I, Vazquez L, Lopez-Jimenez J, et al. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses. 2023. doi:10.3390/v15102066
BibTeX
@article{Piana2023,
author = {Piñana, José Luis and Heras, Inmaculada and Aiello, Tommaso Francesco and García-Cadenas, Irene and Vazquez, Lourdes and Lopez-Jimenez, Javier and Chorão, Pedro and Aroca, Cristina and García-Vidal, Carolina and Arroyo, Ignacio and Soler-Espejo, Eva and López-Corral, Lucia and Avendaño-Pita, Alejandro and Arrufat, Anna and Garcia-Gutierrez, Valentín and Arellano, Elena and Hernández-Medina, Lorena and González-Santillana, Clara and Morell, Julia and Hernández-Rivas, José Ángel and Rodriguez-Galvez, Paula and Mico-Cerdá, Mireia and Guerreiro, Manuel and Campos, Diana and Navarro, David and Cedillo, Ángel and Martino, Rodrigo and Solano, Carlos and Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC), Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)},
title = {Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15102066}
}
EUVIMED